WIKIMEDIA, SLASHME While Turing Pharmaceuticals CEO Martin Shkreli said his firm would lower the price of its toxoplasmosis drug Daraprim following a controversial price hike, he didn’t say by how much or when. But some patients may not have to wait much longer for a low-cost alternative to the $750-per-pill treatment. San Diego-based Imprimis Pharmaceuticals today (October 22) announced that it would make a compounded drug formulation containing Daraprim’s active ingredient, pyrimethamine, available for less than $1 per pill—close to what the treatment cost before Turing acquired rights to Daraprim from CorePharma. Physicians can prescribe such compounded drug formulations when commercially available drugs do not meet the needs of a given patient, in accordance with federal and state law, Imprimis explained.

“This is not the first time a sole supply generic drug—especially one that has been approved for use as long as Daraprim—has had its price increased suddenly...

Hat tip: Ars Technica

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?